The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not reduce 28-day all-cause mortality.
Evidence at a glance
- The trial randomized 1,106 adults; 1,089 were included in the modified intention-to-treat analysis.
- Twenty-eight-day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo.
- The hazard ratio was 0.99 (95% CI 0.77–1.27; P=0.93), and no secondary or safety outcome differed significantly.
Study record
The primary endpoint was death from any cause within 28 days. The near-unity hazard ratio and confidence interval crossing one provide no clear evidence of mortality reduction in the overall trial population.
Results in context
Prespecified subgroup interactions by age and diabetes generated possible differential signals. Subgroups are useful for designing future studies, but they do not reverse a neutral primary result and should not be advertised as established indications.
A 2025 meta-analysis pooled 11 randomized trials with 1,927 participants and found an overall odds ratio of 0.73. Yet its high-quality and multicenter subsets were not statistically significant, and trial-sequential analysis judged the available sample inadequate. The large TESTS result therefore belongs at the center of any current summary.
What the evidence cannot establish
One national trial may not represent every health system or sepsis phenotype.
Subgroup effects require confirmation and should remain hypothesis-generating.
A clinical trial of a finished intervention does not validate an unrelated research lot.
Sources & editorial method
The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, study size, model/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- TESTS phase 3 thymosin alpha-1 sepsis trialPrimary 2025 multicenter trial; PMID 39814420.
- 2025 thymosin alpha-1 sepsis meta-analysisEleven RCTs with quality and trial-sequential analyses; PMID 40969554.
- PubChem Thymalfasin recordSequence, formula, mass and synonym record; CID 16130571.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
